Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets.

After a short period of pseudoatrophy, treatment with cladribine 3.5 mg/kg significantly reduced GM atrophy in comparison with placebo. This supports the relevance of GM damage in MS and may have important implications for physical and cognitive disability progression.